IP Library Granted Patent US 8,354,510
Granted Patent B2
US 8,354,510 · App. 12/568,854 · Granted Jan 15, 2013

Mutant protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,354,510
App. No.
12/568,854
Granted
Jan 15, 2013
Kind
B2
Abstract

The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

Claims (10)

1. In a method of separating one or more antibodies from a liquid, which method comprises:

(a) contacting said liquid with a separation matrix comprising ligands immobilised to a support;

(b) allowing antibodies to adsorb to said matrix by interaction with said ligands;

(c) optionally washing the adsorbed antibodies; and

(d) recovering antibodies by contacting said matrix with an eluent which releases the antibodies;

the improvement being a mutated protein A-based ligand having a N23T mutation in the B-domain of wild-type Staph protein A defined by SEQ ID N:1 or in protein Z defined by SEQ ID NO: 2 and further comprises a second mutation at position 43 of SEQ ID NO:2, which protein confers an increased chemical stability at alkaline pH-value.

2. The method of claim 1 , wherein the recovery of antibodies is achieved by adding an eluent having a pH in the range of 3.8-3.9.

3. The method of claim 1 , wherein at least 80% of the antibodies are recovered using an eluent having a pH in the range of 3.7-3.9.

4. The method of claim 1 , wherein at least 90% of the antibodies are recovered using an eluent having a pH in the range of 3.7-3.9.

5. The method of claim 1 , wherein at least 95% of the antibodies are recovered using an eluent having a pH in the range of 3.7-3.9.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2009
From: HOBER, SOPHIA; JOHANSSON, HANS J.
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 023296/0911 →